SIRT2 and brain neoplasm: Collectively, these findings highlight SIRT2 as a critical molecular target in SMARCB1-deleted ATRT, indicating that therapeutic strategies aimed at SIRT2 inhibition may offer a novel approach for treating this highly aggressive pediatric brain tumor.